Healthcare provider profile · identity verified

Deborah A Hall, MD

Family Practice · BELLINGHAM, WA · NPI 1245221027

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	207	55
Lisinopril	Lisinopril	162	43
Levothyroxine Sodium	Levothyroxine Sodium	160	30
Metformin Hcl	Metformin Hcl	149	41
Omeprazole	Omeprazole	144	32
Rosuvastatin Calcium	Rosuvastatin Calcium	141	38
Amlodipine Besylate	Amlodipine Besylate	124	37
Hydrochlorothiazide	Hydrochlorothiazide	103	29
Alendronate Sodium	Alendronate Sodium	95	26
Losartan Potassium	Losartan Potassium	89	27
Gabapentin	Gabapentin	88	22
Escitalopram Oxalate	Escitalopram Oxalate	73	17
Pravastatin Sodium	Pravastatin Sodium	72	15
Albuterol Sulfate Hfa	Albuterol Sulfate	68	35
Trazodone Hcl	Trazodone Hcl	65	16
Estradiol	Estradiol	64	26
Pantoprazole Sodium	Pantoprazole Sodium	63	suppressed
Simvastatin	Simvastatin	59	15
Sertraline Hcl	Sertraline Hcl	57	16
Metoprolol Succinate	Metoprolol Succinate	52	16
Fluoxetine Hcl	Fluoxetine Hcl	50	14
Duloxetine Hcl	Duloxetine Hcl	48	12
Metoprolol Tartrate	Metoprolol Tartrate	47	13
Mirtazapine	Mirtazapine	41	suppressed
Allopurinol	Allopurinol	39	12
Atenolol	Atenolol	37	11
Xarelto	Rivaroxaban	34	suppressed
Cephalexin	Cephalexin	32	16
Tamsulosin Hcl	Tamsulosin Hcl	32	suppressed
Ozempic	Semaglutide	30	suppressed
Lovastatin	Lovastatin	28	suppressed
Fluticasone Propionate	Fluticasone Propionate	27	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	27	suppressed
Carvedilol	Carvedilol	26	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	25	suppressed
Montelukast Sodium	Montelukast Sodium	23	suppressed
Spiriva Respimat	Tiotropium Bromide	23	suppressed
Enalapril Maleate	Enalapril Maleate	22	suppressed
Meloxicam	Meloxicam	22	suppressed
Bupropion Hcl	Bupropion Hcl	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Ibandronate Sodium	Ibandronate Sodium	20	suppressed
Jardiance	Empagliflozin	20	suppressed
Furosemide	Furosemide	19	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Eliquis	Apixaban	18	suppressed
Hydrocortisone	Hydrocortisone	18	suppressed
Oxycodone Hcl	Oxycodone Hcl	18	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Symbicort	Budesonide/Formoterol Fumarate	17	suppressed
Tramadol Hcl	Tramadol Hcl	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Arnuity Ellipta	Fluticasone Furoate	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Finasteride	Finasteride	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Prednisone	Prednisone	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Risperidone	Risperidone	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	12	suppressed
Alvesco	Ciclesonide	11	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error